3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
29
Gastrointestinal
17
Gynecologic
7
Tumor-Agnostic
5
Thoracic
5
CNS
4
Sarcoma
3
Head & Neck
3
Genitourinary
2
Dermatologic
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
77
Nivolumab
64
Ipilimumab
40
Specimen Handling
33
Magnetic Resonance Spectroscopy
27
Cyclophosphamide
26
Biopsy
20
cemiplimab
16
fludarabine
14
Radiosurgery
14
relatlimab
13
CTLA-4 Antigen
13
binimetinib
12
Opdualag
12
trametinib
11
fludarabine phosphate
11
avelumab
9
Immunoglobulin G
9
Blood Specimen Collection
9
lifileucel
8
dabrafenib
8
atezolizumab
8
Radiotherapy
8
Disulfides
8
encorafenib
7
aldesleukin
7
X-Rays
7
Paclitaxel
7
Standard of Care
6
Interleukin-2
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
trastuzumab deruxtecan
×
Dermatologic
×
90 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled